#USA #New Orleans #VUNO #DeepCARS #AACN NTI

VUNO Unveils DeepCARS® at AACN NTI 2025

In an exciting introduction at the 2025 National Teaching Institute & Critical Care Exposition (NTI), VUNO, a leading global medical AI firm, showcased its flagship product, VUNO Med®–DeepCARS®. Hosted by the American Association of Critical-Care Nurses (AACN) from May 19 to May 21 at the Ernest N. Morial Convention Center in New Orleans, this event offered critical care professionals an insightful look into VUNO's groundbreaking technology.

What is DeepCARS?

DeepCARS is an advanced AI-powered device designed to predict the likelihood of in-hospital cardiac arrest within a 24-hour window. This technology continuously monitors vital signs—including blood pressure, heart rate, respiratory rate, and body temperature—facilitating timely clinical interventions. The integration of DeepCARS into patient care signifies a significant leap forward in proactive healthcare, ensuring clinicians receive crucial insights that can lead to life-saving measures.

Robert Tingley, VUNO's Vice President of Business Development, expressed enthusiasm about the solution’s potential. "Collaborating with AACN members has reaffirmed how DeepCARS can meaningfully contribute to both hospital efficiency and patient safety, empowering clinicians with timely insights that lead to proactive, life-saving care," he stated. His gratitude towards the critical care community highlighted VUNO’s commitment to understanding and addressing the needs of current healthcare practices.

Engagement at AACN NTI 2025

During the event, VUNO's presence drew considerable attention from clinical professionals, particularly members of Rapid Response Teams (RRTs). These teams are integral in identifying patient deterioration at early stages, and the interest in DeepCARS underscores the demand for innovative solutions in their operations. VUNO team members—including Tingley, Area Sales Director Andrew Abbring, and Director of Product Management Tae Min Son—engaged in meaningful conversations with healthcare stakeholders, aiming to better understand the workflows and requirements of hospitals across the U.S.

Real-World Implementation

DeepCARS has already made significant contributions to patient safety, with over 48,000 hospital beds in South Korea employing the technology. This includes implementation in 20 tertiary general hospitals where it has become a staple in routine care. Furthermore, in 2023, DeepCARS received Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA), and it is currently undergoing the 510(k) clearance process, signaling its future availability in the U.S. market.

Future Prospects

VUNO's continued focus on integrating its technologies into clinical workflows highlights its commitment to improving patient care and outcomes. As the company seeks to establish a stronger foothold in the U.S., it endeavors to collaborate closely with healthcare providers, ensuring that its solutions fit seamlessly into existing practices.

About VUNO

Founded in Seoul in 2014, VUNO has emerged as a pioneer in medical AI innovations. Recognized as the developer of the nation’s first approved AI-powered medical device, VUNO utilizes cutting-edge AI technology to analyze a wide spectrum of medical data—from biosignals like ECG and respiratory rates to medical imaging, including X-rays and CT scans. VUNO’s commitment to patient-centered innovation aims to democratize access to high-quality healthcare globally, making it an essential player in the industry’s future.

As medical AI continues to evolve, solutions like DeepCARS represent not just technological advancements but a paradigm shift in how healthcare can potentially save lives, one prediction at a time.